Clinical lymphoma, myeloma & leukemia

The journal describes itself as a peer-reviewed monthly journal publishing original articles on clinical and translational research in lymphoma, myeloma and leukaemia, devoted to detection, diagnosis, prevention and treatment of these diseases and related disorders including macroglobulinaemia, amyloidosis and plasma cell dyscrasias. Stated areas of interest include clinical research and mechanistic approaches, drug sensitivity and resistance, gene and antisense therapy, pathology, markers and prognostic indicators, chemoprevention, multimodality therapy and integration of approaches. ScienceDirect describes it as a Transformative Journal that offers authors a choice of open access or subscription publication and is committed to transitioning to fully open access. NLM records the title from 2010 as the successor to Clinical Lymphoma and Myeloma, first published in Dallas by the Cancer Media Group and from 2011 by Elsevier, bimonthly in the NLM record, indexed in MEDLINE and PubMed. Not listed in DOAJ.